EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial

Ying Liu, Jacquelyn Bainbridge, Stefan Sillau, Sarah Rajkovic iD, Michelle Adkins iD, Christopher H Domen iD, John A Thompson iD, Tristan Seawalt, Jost Klawitter iD, Cristina Sempio iD, Grace Chin, Lisa Forman und 6 weitere

Movement Disorders · 2024-05 · 39 (5) · 863-875

DOI: 10.1002/mds.29768 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 15.03.2024. Verfasst von Ying Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Cannabidiol, Dronabinol, Parkinson Disease. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, Colorado Department of Public Health and Environment Medical marijuana research grant program, contract.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cannabis use is frequent in Parkinson's disease (PD), despite inadequate evidence of benefits and risks.

Objective

The aim is to study short‐term efficacy and tolerability of relatively high cannabidiol (CBD)/low Δ‐9‐tetrahydrocannabinol (THC) to provide preliminary data for a longer trial.

Methods

Persons with PD with ≥20 on motor Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) who had negative cannabis testing took cannabis extract (National Institute of Drug Abuse) oral sesame oil solution for 2 weeks, increasing to final dose of 2.5 mg/kg/day. Primary outcome was change in motor MDS‐UPDRS from baseline to final dose.

Results

Participants were randomized to CBD/THC (n = 31) or placebo (n = 30). Mean final dose (CBD/THC group) was 191.8 ± 48.9 mg CBD and 6.4 ± 1.6 mg THC daily. Motor MDS‐UPDRS was reduced by 4.57 (95% CI, −8.11 to −1.03; P = 0.013) in CBD/THC group, and 2.77 (−4.92 to −0.61; P = 0.014) in placebo; the difference between groups was non‐significant: −1.80 (−5.88 to 2.27; P = 0.379). Several assessments had a strong placebo response. Sleep, cognition, and activities of daily living showed a treatment effect, favoring placebo. Overall adverse events were mild and reported more in CBD/THC than placebo group. On 2.5 mg/kg/day CBD plasma level was 54.0 ± 33.8 ng/mL; THC 1.06 ± 0.91 ng/mL.

Conclusions

The brief duration and strong placebo response limits interpretation of effects, but there was no benefit, perhaps worsened cognition and sleep, and there was many mild adverse events. Longer duration high quality trials that monitor cannabinoid concentrations are essential and would require improved availability of research cannabinoid products in the United States. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDronabinolParkinson DiseaseHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

Parkinson's diseasecannabidiolcannabis

Substanzen

CannabidiolDronabinol

Autor:innen und Institutionen

  • Department of Neurology, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, USA.
  • Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Neurosciences, University of Colorado Hospital, Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Neurosurgery, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, USA.
  • Department of Anesthesiology, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, USA.
  • Department of Medicine, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Sarah Rajkovic, Michelle Adkins, Christopher H Domen, John A Thompson, Jost Klawitter, Cristina Sempio, Maureen Anne Leehey

Förderung

  • NCATS NIH HHS
  • Colorado Department of Public Health and Environment Medical marijuana research grant program, contract

Zitieren

APA

Liu, Y., Bainbridge, J., Sillau, S., Rajkovic, S., Adkins, M., Domen, C. H., Thompson, J. A., Seawalt, T., Klawitter, J., Sempio, C., Chin, G., Forman, L., Fullard, M., Hawkins, T., Seeberger, L., Newman, H., Vu, D., & Leehey, M. A. (2024). Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial. Movement Disorders, 39(5), 863-875. https://doi.org/10.1002/mds.29768

Vancouver

Liu Y, Bainbridge J, Sillau S, Rajkovic S, Adkins M, Domen CH, et al. Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial. Movement Disorders. 2024;39(5):863-875. doi:10.1002/mds.29768

BibTeX
@article{Liu2024,
  author = {Liu, Ying and Bainbridge, Jacquelyn and Sillau, Stefan and Rajkovic, Sarah and Adkins, Michelle and Domen, Christopher H and Thompson, John A and Seawalt, Tristan and Klawitter, Jost and Sempio, Cristina and Chin, Grace and Forman, Lisa and Fullard, Michelle and Hawkins, Trevor and Seeberger, Lauren and Newman, Heike and Vu, David and Leehey, Maureen Anne},
  title = {Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial},
  journal = {Movement Disorders},
  year = {2024},
  volume = {39},
  number = {5},
  pages = {863--875},
  doi = {10.1002/mds.29768}
}
Kostenlos starten →